Observations placeholder

Sulfasalazine (brand name Azulfidine in the U.S., Salazopyrin and Sulazine in Europe and Hong Kong) was developed in the 1950s specifically to treat rheumatoid arthritis. Sulfasalazine is a sulfa drug, a derivative of mesalazine, and is formed by combining sulfapyridine and salicylate with an azo bond. It may be abbreviated SSZ.

Sulfasalazine is used in the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is also indicated for use in rheumatoid arthritis and used in other types of inflammatory arthritis (e.g. psoriatic arthritis) .

It is classified as a DMARD - Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid arthritis to slow down disease progression. The term is often used in contrast to non-steroidal anti-inflammatory drug (which refers to agents that treat the inflammation but not the underlying cause) and steroids (which blunt the immune response but are insufficient to slow down the progression of the disease).

On Oct, 10, 2015: 4,374 people reported to have side effects when taking Azulfidine. Among them, 7 people (0.16%) have Hallucination.

Time on Azulfidine when people have Hallucination  :

< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Hallucination100.00%0.00%0.00%0.00%0.00%0.00%0.00%

On Oct, 10, 2015: 1,197 people reported to have side effects when taking Azulfidine en-tabs. Among them, 1 people (0.08%) has Hallucination.

On Sep, 24, 2015: 4,374 people reported to have side effects when taking Azulfidine. Among them, 41 people (0.94%) have Death.

Time on Azulfidine when people have Death  :

< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death0.00%66.67%33.33%0.00%0.00%0.00%0.00%

On Oct, 6, 2015: 1,197 people reported to have side effects when taking Azulfidine en-tabs. Among them, 7 people (0.58%) have Death.